- Home
- XOMA vs RIGL Comparison
XOMA vs RIGL Comparison
Compare XOMA & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | XOMA | RIGL |
|---|---|---|
| Founded | 1981 | 1996 |
| Country | United States | United States |
| Employees | 14 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 471.6M | 564.7M |
| IPO Year | N/A | 2000 |
Fundamental Metrics
Financial Performance| Metric | XOMA | RIGL |
|---|---|---|
| Price | $41.67 | $29.04 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 3 |
| Target Price | ★ $52.50 | $45.67 |
| AVG Volume (30 Days) | 371.4K | ★ 386.4K |
| Earning Date | 05-08-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 1867.68 |
| EPS | N/A | ★ 0.44 |
| Revenue | N/A | ★ $294,282,000.00 |
| Revenue This Year | $24.59 | N/A |
| Revenue Next Year | N/A | $12.75 |
| P/E Ratio | ★ $29.64 | $72.85 |
| Revenue Growth | N/A | ★ 64.15 |
| 52 Week Low | $22.29 | $18.14 |
| 52 Week High | $42.81 | $52.24 |
Technical Indicators
Market Signals| Indicator | XOMA | RIGL |
|---|---|---|
| Relative Strength Index (RSI) | 66.49 | 49.32 |
| Support Level | $24.38 | $28.08 |
| Resistance Level | $42.00 | $31.89 |
| Average True Range (ATR) | 0.66 | 1.92 |
| MACD | -0.32 | 0.20 |
| Stochastic Oscillator | 63.02 | 49.21 |
Price Performance
Historical ComparisonAbout XOMA XOMA Corporation
XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates. The Company's drug royalty aggregator business is mainly focused on the acquisition of early to mid-stage clinical assets. Geographically, the company operates in Switzerland, the United States, Asia Pacific, Europe, and other regions.
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, REZLIDHIA (olutasidenib), GAVRETO (pralsetinib), R289, and Ocadusertib (Systemic) - Eli Lilly.